双[4-甲氧基-3-(1-甲基乙基)苯基]-四氟溴化碘 | 156740-76-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 双[4-甲氧基-3-(1-甲基乙基)苯基]-四氟溴化碘
• 英文名称: Bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate
• 英文别名: bis(4-methoxy-3-propan-2-ylphenyl)iodanium;tetrafluoroborate
• CAS: 156740-76-0
• 化学式: C20H26BF4IO2
• 分子量: 512.1
• InChiKey: VPZNSQWCBWZHJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.38
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  双[4-甲氧基-3-(1-甲基乙基)苯基]-四氟溴化碘 、 2,6-二甲基-4-硝基苯酚 生成 3,5-二甲基-4-(3'-异丙基-4'-甲氧基苯氧基)-硝基苯
  参考文献：
  名称：

  Malonamic acids and derivatives thereof as thyroid receptor ligands

  摘要：

  本发明涉及新型甲状腺受体配体，更具体地涉及公式I的马隆酰胺及其衍生物，可用于治疗肥胖、超重状态、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退、甲状腺癌和相关疾病，如糖尿病、动脉硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松症和脱发。本发明还提供了治疗这些疾病和疾病的方法、药物组合物和工具包。

  公开号：

  US06664291B2

文献信息

• Novel Phosphorus-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20100081634A1

  公开（公告）日：2010-04-01

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有膦酸的T3模拟物化合物及其单酯、立体异构体、药学上可接受的盐、共晶体和前药及其药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征X和糖尿病的用途。
• Heteroacetic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05401772A1

  公开（公告）日：1995-03-28

  Disclosed are compounds of formula ##STR1## wherein R is hydroxy, esterified hydroxy or etherified hydroxy; R.sub.1 is halogen, trifluoromethyl or lower alkyl; R.sub.2 is halogen, trifluoromethyl or lower alkyl; R.sub.3 is halogen, trifluoromethyl, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkyl-lower alkyl; or R.sub.3 is the radical ##STR2## wherein R.sub.8 is hydrogen, lower alkyl, aryl, cycloalkyl, aryl-lower alkyl or cycloalkyl-lower alkyl; R.sub.9 is hydroxy or acyloxy; R.sub.10 represents hydrogen or lower alkyl; or R.sub.9 and R.sub.10 together represent oxo; R.sub.4 is hydrogen, halogen, trifluoromethyl or lower alkyl; X is --NR.sub.7, S or O; W is O or S; R.sub.5 represents hydrogen, lower alkyl or aryl-lower alkyl;and R.sub.6 represents hydrogen; or R.sub.5 and R.sub.6 together represent oxo provided that X represents --NR.sub.7; R.sub.7 represents hydrogen or lower alkyl; Z represents carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or as a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; which are useful as hypocholesteremic agents.

  本发明涉及公式##STR1##的化合物，其中R为羟基，酯化羟基或醚化羟基；R.sub.1为卤素，三氟甲基或较低的烷基；R.sub.2为卤素，三氟甲基或较低的烷基；R.sub.3为卤素，三氟甲基，较低的烷基，芳基，芳基-较低的烷基，环烷基或环烷基-较低的烷基；或R.sub.3为基团##STR2##其中R.sub.8为氢，较低的烷基，芳基，环烷基，芳基-较低的烷基或环烷基-较低的烷基；R.sub.9为羟基或酰氧基；R.sub.10表示氢或较低的烷基；或R.sub.9和R.sub.10一起表示氧代；R.sub.4为氢，卤素，三氟甲基或较低的烷基；X为--NR.sub.7，S或O；W为O或S；R.sub.5表示氢，较低的烷基或芳基-较低的烷基；R.sub.6表示氢；或R.sub.5和R.sub.6一起表示氧代，前提是X表示--NR.sub.7；R.sub.7表示氢或较低的烷基；Z表示羧基，以药学上可接受的酯或药学上可接受的酰胺衍生物的形式衍生的羧基；以及其药学上可接受的盐；其作为降低胆固醇的药物。
• Compounds active at the glucocorticoid receptor
  申请人：——

  公开号：US20030166725A1

  公开（公告）日：2003-09-04

  This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in therapy and in the regulation of metabolism, especially lowering blood glucose levels. The compounds referred to are compounds according to the formula (I).

  本发明涉及一种新型化合物，其为肝脏选择性糖皮质激素受体拮抗剂，涉及制备这种化合物的方法，以及使用这种化合物进行治疗和调节代谢的方法，特别是降低血糖水平。所涉及的化合物是根据公式(I)的化合物。
• Thyroid receptor ligands
  申请人：——

  公开号：US20010051645A1

  公开（公告）日：2001-12-13

  The invention provides thiazolidinedione, oxadiazolidinedione, and triazolone compounds of Formula (I) which compounds are thyroid receptor ligands. 1 The invention further provides pharmaceutical compositions and kits comprising such compounds and methods of treating obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer, diabetes, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesterolemia, depression, and osteoporosis using such compounds.

  该发明提供了公式(I)的噻唑烷二酮、噁唑烷二酮和三唑酮化合物，这些化合物是甲状腺受体配体。该发明还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物治疗肥胖、超重、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退症、甲状腺癌、糖尿病、动脉粥样硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症和骨质疏松症的方法。
• Benzofuran derivatives
  申请人：——

  公开号：US20040220415A1

  公开（公告）日：2004-11-04

  The invention relates to novel benzofuran derivatives, to processes for preparing them and to their uses in medicaments.

  本发明涉及新型苯并呋喃衍生物，其制备方法以及在药物中的应用。